Compare Roundhill NVDA WeeklyPay ETF (NVDW) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill NVDA WeeklyPay ETF vs ResMed Inc. — how do they compare? Roundhill NVDA WeeklyPay ETF trades at $37.16, while ResMed Inc. trades at $219.5 (market cap $31.89B). The key difference: ResMed Inc. pays a 1.19% dividend while Roundhill NVDA WeeklyPay ETF pays none, and ResMed Inc. is trading nearer its 52-week high, Roundhill NVDA WeeklyPay ETF nearer its low. Which is the better fit depends on your goals.
| NVDW | RMD | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $52.33 | $283.28 |
52-Week Low | $31.88 | $182.82 |
Market Cap | — | $31.89B |
Enterprise Value | — | $31.24B |
Dividend Yield | — | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDW (Roundhill NVDA WeeklyPay ETF) trades at $37.60, down 3.22% with a bullish technical signal from moving averages. The ETF provides leveraged exposure to Nvidia with weekly dividend payments, though key valuation ratios remain unavailable. Recent news highlights its high-yield income strategy tied to NVDA's performance, with payouts fluctuating based on underlying stock volatility.
The outlook depends heavily on Nvidia's continued earnings strength and AI market momentum. Key risks include leverage amplification during NVDA downturns and variable dividend sustainability. Investors seeking weekly income from tech exposure may find value, but must monitor NAV erosion risks amid sector volatility.
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Roundhill NVDA WeeklyPay ETF
NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
